Business Wire

Velodyne Lidar Commends NHTSA Plan to Update NCAP

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.)

NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and blind spot intervention. The proposal asks for comments on how best to develop a NHTSA rating system for ADAS technologies. It also requests comments on potential approaches for conveying this information on the Monroney label, which is displayed on all new automobiles and provides important vehicle information to consumers.

“NHTSA’s proposal has the potential to save lives. Adding ADAS to NCAP is an excellent step forward in advancing safety features in cars and educating consumers on what those features can and cannot do,” said Mircea Gradu, PhD, Senior Vice President of Product and Quality, Velodyne Lidar. “Velodyne has long been engaged with NHTSA and other auto safety leaders on how to standardize ADAS features and establish a rating system that measures ADAS levels of performance. We are eager to work with the agency and all stakeholders on completing this important initiative.”

Velodyne has for years been dedicated to testing lidar sensors and developing safety metrics for ADAS systems. NHTSA’s new plans allow Velodyne to share the company’s findings, weighing in on the capabilities of lidar-centric ADAS systems which have superior performance after sundown, an advantage over current radar+camera-based ADAS solutions. Lidar is self-illuminating; its array of laser beams can accurately perceive the environment in darkness as well as in daylight. Lidar has long been a key sensor for autonomous driving and now Velodyne is applying lidar technology for ADAS vehicle safety, planning to offer software and lidar system solutions in increasing increments of safety and protection.

Five-Diamond ADAS Rating System

Velodyne has a long-standing commitment to fostering understanding of the safety and mobility benefits of advanced driving capabilities to consumer, business, government, public safety and community audiences. These efforts include developing a framework for a five-diamond rating system, aimed at establishing standardized performance assessments of ADAS features. The system is designed to encourage transparency in the marketplace and promote the maximum positive effect of ADAS technologies.

The five-level rating system utilizes diamonds to mark significant milestone achievements in vehicle system performance. The foundational ADAS technologies included in the five-diamond rating system are adaptive cruise control, lane keep assistance, automatic emergency braking, automatic emergency steering and blind spot monitoring.

Velodyne has presented the proposed system to encourage refinement and quantification of the performance descriptors to organizations that include NHTSA, SAE International, Insurance Institute for Highway Safety (IIHS), National Transportation Safety Board (NTSB) and International Alliance for Mobility Testing and Standardization (IAMTS). Velodyne developed a white paper on the rating system, called “An ADAS Feature Rating System: Proposing a New Industry Standard.”

Velodyne envisions the ADAS assessment system results can be incorporated into the Monroney label. Velodyne has developed a proposed ADAS rating label for government and industry review. It is similar to the current NHTSA-developed crash-worthiness label and can be used to educate consumers on vehicle ADAS capabilities before they make car purchases.

Improving ADAS to Reduce Nighttime Dangers to Pedestrians

Velodyne has also called for increased testing of ADAS performance in dark nighttime scenarios. This expansion would address a gap in current testing protocols, which primarily look at daytime conditions and largely overlook the risks to pedestrians from ADAS features that perform poorly in dark nighttime conditions.

Over 6,000 pedestrians are killed every year in traffic-related crashes in the United States with the vast majority of fatalities occurring in dark conditions, per NHTSA reports. Current ADAS, with pedestrian automatic emergency braking (PAEB) that utilizes camera and radar technology, frequently fail to protect pedestrians in dark conditions according to independent testing by NHTSA and the American Automobile Association (AAA).

To reflect real-life conditions, Velodyne proposes expanding PAEB testing protocols to include tests conducted in dark nighttime conditions. This change would protect the public and provide consumers useful information on the capabilities and limitations of different pedestrian detection systems.

This proposal is addressed in a Velodyne white paper, “Improving Pedestrian Automatic Emergency Braking (PAEB) in Dark, Nighttime Conditions.” The white paper also includes the results of nighttime PAEB tests conducted by Velodyne. The tests evaluated a highly-rated PAEB system using camera and radar-based technology and Velodyne’s PAEB system that uses Velodyne’s Velarray H800 sensor and Vella™ software. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations
Andrew Hamer
Chief Financial Officer
InvestorRelations@velodyne.com

Media
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release

Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye